The impact of GSTT2B and GSTT1 deletions and selected GSTT2 promoter SNPs [18] on the development of bladder cancer and the response of bladder cancer patients to BCG immunotherapy were determined. This evidence concerns the gene GSTT2B and urinary bladder carcinoma.